IGHE and asthma: 16 Elevated levels of these biomarkers are frequently associated with the presence of atopy and bronchial hyperresponsiveness (BHR)17 and are considered to be sensitive to inhibition by corticosteroids and monoclonal antibodies against IgE, IL‐5 or IL‐5 receptor.1, 12, 17 In contrast, patients who have “non‐type‐2” (also known as “type‐2–low”) severe asthma are frequently characterized by airway neutrophilia, a type‐17 immune signature involving genes such as CXCL1, CXCL2 and CSF318 and disease that is not effectively treated by inhaled corticosteroids or biologics.6